Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$4.45T | 111.4x | 8.62 | R$164.24 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$3.02T | 41.4x | 1.2 | R$85.03 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$2.11T | 10.3x | 0.11 | R$58.27 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$1.85T | 63.7x | -1.67 | R$64.96 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.56T | 20.9x | 0.06 | R$76.73 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.32T | 37.6x | 8.85 | R$71.24 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.28T | 14.6x | 0.2 | R$62.58 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$934.97B | 54.7x | -0.95 | R$61.86 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$893.30B | -62.8x | 0.57 | R$39.23 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$561.74B | 98x | -1.23 | R$228.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$552.24B | -15.5x | 0.08 | R$274.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | B3 | Healthcare | Pharmaceuticals | R$480.55B | 37.9x | 5.02 | R$65.59 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$450.99B | 15.3x | -0.21 | R$44.56 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | B3 | Healthcare | Pharmaceuticals | R$338.53B | 21.4x | -1.34 | R$650.10 | -7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$253.95B | 44.2x | -0.89 | R$80.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$153.60B | 24.1x | -0.43 | R$178.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | B3 | Healthcare | Pharmaceuticals | R$149.11B | 32.7x | 0.18 | R$530.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$107.86B | -43.5x | -0.55 | R$48.05 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin | B3 | Healthcare | Pharmaceuticals | R$72.73B | 51.3x | 0.34 | R$190.10 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | B3 | Healthcare | Pharmaceuticals | R$68.16B | 148.7x | -1.76 | R$179.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Perrigo Company | B3 | Healthcare | Pharmaceuticals | R$20.39B | -34x | 0.4 | R$144.53 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hypera | B3 | Healthcare | Pharmaceuticals | R$17.13B | 11.7x | -4.34 | R$26.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.3% Upside | Upgrade to Pro+ | |
Hypera | B3 | Healthcare | Pharmaceuticals | R$16.61B | 9.8x | -4.36 | R$26.26 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42% Upside | Upgrade to Pro+ | |
Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.35B | 10.8x | -0.35 | R$13.19 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.2% Downside | Upgrade to Pro+ | |
Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$1.13B | 21.1x | 0.1 | R$21 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | |
CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$605.14M | 3.4x | -0.15 | R$1.86 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |